Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

注射用亚锡替曲膦 - NMPA Drug Approval Details

Approvals/NMPA/Tetrofosmin and Stannous Chloride for Injection

Approved

化学药品

Tetrofosmin and Stannous Chloride for Injection

GE Healthcare AS🇨🇳 National Medical Products Administration

Approval Date: Mar 29, 2022
Approval ID: 8FFrC9oe0Aa
Company: GE Healthcare AS
Type: 化学药品

Approval Details

Approval Id: 8FFrC9oe0Aa
Approval Number: 国药准字HJ20220026
Generic Name: 注射用亚锡替曲膦
Generic Name En: Tetrofosmin and Stannous Chloride for Injection
Drug Type: 化学药品
Dosage Form: 注射剂
Strength: 每瓶内含替曲膦0.23mg与亚锡15.8μg
Reg Date: 2022-03-29
Expired Date: 2027-03-28
Company Name: GE Healthcare AS
Production Company Name: GE Healthcare AS
Company Detail Path: /organization/ge-healthcare-as
Production Company Detail Path: /organization/ge-healthcare-as

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Mar 29, 2022

Approval ID

8FFrC9oe0Aa

Type

化学药品

Back to NMPA Approvals